HRP20110773T1 - Derivati 2,3,4,9-tetrahidro-1h-karbazola kao antagonisti crth2 receptora - Google Patents

Derivati 2,3,4,9-tetrahidro-1h-karbazola kao antagonisti crth2 receptora Download PDF

Info

Publication number: HRP20110773T1
Authority: HR; Croatia
Prior art keywords: tetrahydro; carbazol; acetic acid; phenyl; carbamoyl
Prior art date: 2004-12-27

Application number

HR20110773T

Other languages

English (en)

Croatian (hr)

Inventor

Fecher Anja

Fretz Heinz

Riederer Markus

Original Assignee

Actelion Pharmaceuticals Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-27

Filing date

2005-12-22

Publication date

2011-11-30

2005-12-22 Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.

2011-11-30 Publication of HRP20110773T1 publication Critical patent/HRP20110773T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

HR20110773T 2004-12-27 2005-12-22 Derivati 2,3,4,9-tetrahidro-1h-karbazola kao antagonisti crth2 receptora HRP20110773T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2004014719		2004-12-27
PCT/IB2005/054380 WO2006070325A2 (en)	2004-12-27	2005-12-22	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Publications (1)

Publication Number	Publication Date
HRP20110773T1 true HRP20110773T1 (hr)	2011-11-30

Family

ID=36499938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110773T HRP20110773T1 (hr)	2004-12-27	2005-12-22	Derivati 2,3,4,9-tetrahidro-1h-karbazola kao antagonisti crth2 receptora

Country Status (26)

Country	Link
US (1)	US8039474B2 (de)
EP (1)	EP1833791B1 (de)
JP (1)	JP5137240B2 (de)
KR (1)	KR101329903B1 (de)
CN (1)	CN101084190B (de)
AR (1)	AR052549A1 (de)
AT (1)	ATE518834T1 (de)
AU (1)	AU2005320964B2 (de)
BR (1)	BRPI0519280A2 (de)
CA (1)	CA2594280C (de)
CY (1)	CY1112376T1 (de)
DK (1)	DK1833791T3 (de)
ES (1)	ES2369782T3 (de)
HR (1)	HRP20110773T1 (de)
IL (1)	IL184233A0 (de)
MX (1)	MX2007007691A (de)
MY (1)	MY144897A (de)
NO (1)	NO20073059L (de)
NZ (1)	NZ556657A (de)
PL (1)	PL1833791T3 (de)
PT (1)	PT1833791E (de)
RU (1)	RU2404163C2 (de)
SI (1)	SI1833791T1 (de)
TW (1)	TW200633978A (de)
WO (1)	WO2006070325A2 (de)
ZA (1)	ZA200705085B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
MY147588A (en)	2006-08-07	2012-12-31	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
CA2713139C (en)	2008-02-01	2013-04-23	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2245022A4 (de)	2008-02-25	2012-02-22	Panmira Pharmaceuticals Llc	Antagonisten von prostaglandin-d2-rezeptoren
JP2011526281A (ja)	2008-06-24	2011-10-06	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
GB2463788B (en)	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8394819B2 (en) *	2009-02-24	2013-03-12	Merck Sharp & Dohme Corp.	Indole derivatives as CRTH2 receptor antagonists
WO2011014587A2 (en)	2009-07-31	2011-02-03	Amira Pharmaceuticals, Inc.	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
CN102596902A (zh)	2009-08-05	2012-07-18	潘米拉制药公司	Dp2拮抗剂及其用途
CA2790139C (en)	2010-03-22	2018-03-13	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
US8927559B2 (en)	2010-10-11	2015-01-06	Merck Sharp & Dohme Corp.	Quinazolinone-type compounds as CRTH2 antagonists
EP2457900A1 (de)	2010-11-25	2012-05-30	Almirall, S.A.	Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
JP5964945B2 (ja)	2011-04-14	2016-08-03	アクテリオンファーマシューティカルズリミテッドＡｃｔｅｌｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
JP5629403B2 (ja) *	2011-06-17	2014-11-19	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｒｔｈ２受容体モジュレータとしてのシクロアルキル縮合テトラヒドロキノリン
CA2939892C (en)	2014-03-17	2020-03-31	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh)	2014-03-18	2016-11-09	埃科特莱茵药品有限公司	氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
CN108026093B (zh)	2015-09-15	2021-11-16	爱杜西亚药品有限公司	结晶形式
CN117143007B (zh) *	2023-08-31	2026-01-09	陕西科技大学	一种四氢咔唑衍生物及其光催化合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1335228A (en) *	1970-06-02	1973-10-24	Sterling Drug Inc	Tetrahydrocarbazoles
US3687969A (en) *	1970-06-02	1972-08-29	Sterling Drug Inc	9-aroyl-1,2,3,4-tetrahydrocarbazole-3,3-dicarboxylic acids
US3941805A (en) *	1972-11-17	1976-03-02	Sterling Drug Inc.	3-Halomethylcarbonyl-9-benzoyl-1,2,3,4-tetrahydrocarbazoles
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
CA2106642C (en) *	1992-10-14	2005-08-16	Peter Bod	Carbazolone derivatives and process for preparing the same
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
ATE340796T1 (de)	2001-05-23	2006-10-15	Merck Frosst Canada Inc	Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
WO2003051837A2 (de)	2001-12-14	2003-06-26	Zentaris Gmbh	Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
WO2003097042A1 (en)	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Pgd2 receptor antagonist
WO2003097598A1 (en)	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Compound exhibiting pgd 2 receptor antagonism
GB2388540A (en)	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
BR0315681A (pt)	2002-10-30	2005-09-06	Merck Frosst Canada Inc	Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
JPWO2004078719A1 (ja)	2003-03-06	2006-06-08	小野薬品工業株式会社	インドール誘導体化合物およびその化合物を有効成分とする薬剤
EP1631547A1 (de)	2003-05-20	2006-03-08	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl-substituierte cycloalkanoindole zur verwendung als prostaglandin d2 antagonisten
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
WO2004111047A2 (en)	2003-06-12	2004-12-23	Merck Frosst Canada Ltd.	Cycloalkanepyrrolopyridines as dp receptor antagonists
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
WO2005040112A1 (en)	2003-10-14	2005-05-06	Oxagen Limited	Compounds with pgd2 antagonist activity
JP2007508363A (ja)	2003-10-14	2007-04-05	オキサジェンリミテッド	Ｃｒｔｈ２アンタゴニスト活性を有する化合物
GB2407318A (en)	2003-10-23	2005-04-27	Oxagen Ltd	Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en)	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
SE0303180D0 (sv)	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
US7019022B2 (en)	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005073234A2 (en)	2004-01-31	2005-08-11	Actimis Pharmaceuticals, Inc.	Imidazo[1,2-c]pyrimidinylacetic acid derivatives
AU2005229522A1 (en)	2004-03-11	2005-10-13	Actelion Pharmaceuticals Ltd.	Indol-1-yl-acetic acid derivatives
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
CA2577748A1 (en)	2004-08-26	2006-03-02	Actelion Pharmaceuticals Ltd	2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists
MY147588A (en)	2006-08-07	2012-12-31	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives

2005
- 2005-12-22 ES ES05850906T patent/ES2369782T3/es not_active Expired - Lifetime
- 2005-12-22 NZ NZ556657A patent/NZ556657A/en not_active IP Right Cessation
- 2005-12-22 WO PCT/IB2005/054380 patent/WO2006070325A2/en not_active Ceased
- 2005-12-22 KR KR1020077017341A patent/KR101329903B1/ko not_active Expired - Fee Related
- 2005-12-22 DK DK05850906.8T patent/DK1833791T3/da active
- 2005-12-22 JP JP2007547781A patent/JP5137240B2/ja not_active Expired - Fee Related
- 2005-12-22 HR HR20110773T patent/HRP20110773T1/hr unknown
- 2005-12-22 PT PT05850906T patent/PT1833791E/pt unknown
- 2005-12-22 PL PL05850906T patent/PL1833791T3/pl unknown
- 2005-12-22 MX MX2007007691A patent/MX2007007691A/es active IP Right Grant
- 2005-12-22 CA CA2594280A patent/CA2594280C/en not_active Expired - Fee Related
- 2005-12-22 EP EP05850906A patent/EP1833791B1/de not_active Expired - Lifetime
- 2005-12-22 RU RU2007128736/04A patent/RU2404163C2/ru not_active IP Right Cessation
- 2005-12-22 AU AU2005320964A patent/AU2005320964B2/en not_active Ceased
- 2005-12-22 CN CN2005800438848A patent/CN101084190B/zh not_active Expired - Fee Related
- 2005-12-22 SI SI200531395T patent/SI1833791T1/sl unknown
- 2005-12-22 AT AT05850906T patent/ATE518834T1/de active
- 2005-12-22 US US11/722,095 patent/US8039474B2/en not_active Expired - Fee Related
- 2005-12-22 BR BRPI0519280-3A patent/BRPI0519280A2/pt not_active IP Right Cessation
- 2005-12-23 MY MYPI20056197A patent/MY144897A/en unknown
- 2005-12-26 TW TW094146581A patent/TW200633978A/zh unknown
- 2005-12-27 AR ARP050105557A patent/AR052549A1/es not_active Application Discontinuation
2007
- 2007-06-13 ZA ZA200705085A patent/ZA200705085B/xx unknown
- 2007-06-15 NO NO20073059A patent/NO20073059L/no not_active Application Discontinuation
- 2007-06-26 IL IL184233A patent/IL184233A0/en not_active IP Right Cessation
2011
- 2011-11-02 CY CY20111101047T patent/CY1112376T1/el unknown

Also Published As

Publication number	Publication date
CN101084190B (zh)	2011-01-26
US8039474B2 (en)	2011-10-18
ATE518834T1 (de)	2011-08-15
JP2008525426A (ja)	2008-07-17
ZA200705085B (en)	2008-08-27
TW200633978A (en)	2006-10-01
PT1833791E (pt)	2011-10-19
NO20073059L (no)	2007-07-19
DK1833791T3 (da)	2011-10-24
RU2007128736A (ru)	2009-02-10
US20090270414A1 (en)	2009-10-29
AU2005320964A1 (en)	2006-07-06
CA2594280A1 (en)	2006-07-06
CA2594280C (en)	2013-04-23
PL1833791T3 (pl)	2011-12-30
EP1833791B1 (de)	2011-08-03
NZ556657A (en)	2010-10-29
ES2369782T3 (es)	2011-12-05
IL184233A0 (en)	2007-10-31
AR052549A1 (es)	2007-03-21
EP1833791A2 (de)	2007-09-19
CN101084190A (zh)	2007-12-05
HK1111698A1 (en)	2008-08-15
RU2404163C2 (ru)	2010-11-20
JP5137240B2 (ja)	2013-02-06
CY1112376T1 (el)	2015-12-09
WO2006070325A3 (en)	2006-09-14
SI1833791T1 (sl)	2011-11-30
WO2006070325A2 (en)	2006-07-06
KR101329903B1 (ko)	2013-11-14
KR20070104367A (ko)	2007-10-25
MY144897A (en)	2011-11-30
MX2007007691A (es)	2007-08-14
AU2005320964B2 (en)	2011-12-15
BRPI0519280A2 (pt)	2009-01-06

Publication	Publication Date	Title
CA2558545A1 (en)	2005-10-13	Indol-1-yl-acetic acid derivatives
RU2404163C2 (ru)	2010-11-20	Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
US9029387B2 (en)	2015-05-12	Benzonaphthyridinamines as autotaxin inhibitors
Liu et al.	2009	5‐HT6 antagonists as potential treatment for cognitive dysfunction
CA2712990C (en)	2016-09-27	Benzonaphthyridinyl compounds as protein kinase inhibitors and use thereof
ES2524079T3 (es)	2014-12-04	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9H-carbazol y su uso como moduladores del receptor de prostaglandina D2
JP2010516692A (ja)	2010-05-20	化学療法剤に対し抵抗性を有する癌の処置
Hu et al.	2015	Design, synthesis and molecular docking studies of novel indole–pyrimidine hybrids as tubulin polymerization inhibitors
JPH08512284A (ja)	1996-12-24	抗精神病インダゾール誘導体
AU2015260826A1 (en)	2016-11-03	Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
PE20081559A1 (es)	2008-11-20	DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JP2009533338A (ja)	2009-09-17	置換環縮合アジンおよび癌治療におけるそれらの使用
HRP20120044T1 (hr)	2012-02-29	Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-octene kiseline
AR070797A1 (es)	2010-05-05	Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
WO2012089633A1 (fr)	2012-07-05	Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
ES2222828A1 (es)	2005-02-01	Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
ES2366496T3 (es)	2011-10-20	Compuestos de aminoalcoxi arilsulfonamida y su uso como ligandos 5-ht6.
IL198821A (en)	2014-11-30	Compounds 5– (Phiprazinylmethyl) –1– (Arylsulfonyl) –Indol
CN101712675A (zh)	2010-05-26	苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
CA2616669A1 (en)	2007-02-08	Squaric acid derivatives_ii
US10308631B2 (en)	2019-06-04	Selective anti-cancer compounds
FR2969611A1 (fr)	2012-06-29	Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CA2580730A1 (en)	2005-04-07	Tetrahydroindolone derivatives for treatment of neurological conditions
FR2969614A1 (fr)	2012-06-29	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2969610A1 (fr)	2012-06-29	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)